| Vonjo (pacritinib) / SOBI |
| Not yet recruiting | 3 | 358 | US | Enpaxiq (pacritinib) - Baxter Healthcare, CTI BioPharma | Baxter Healthcare, CTI BioPharma | Severe COVID-19 | | | | |
ACTRN12614000740695: Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326) |
|
|
| Recruiting | 3 | 300 | | | Cell Therapeutics Inc., Cell Therapeutics Inc. | Primary Myelofibrosis
| | | | |
2012-004239-21: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia) |
|
|
| Ongoing | 3 | 75 | Europe | pacritinib, SB1518, | CTI BioPharma Corp., CELL THERAPEUTICS INC., CTI BioPharma Corp., Cell Therapeutics Inc | Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | | | | |
2013-004000-19: A study comparing current standard therapies with pacritinib taken by mouth for the treatment of myelofibrosis (either diagnosed alone or after polycythemia vera or essential thrombocytopenia) in patients with a low platelet count |
|
|
| Ongoing | 3 | 50 | Europe | pacritinib, SB1518, | CTI BioPharma Corp., Cell Therapeutics, Inc., CTI BioPharma Corp., Cell Therapeutics, Inc. | Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Thrombocytopenia | | | | |
2020-000111-69: PACIFICA Phase 3: A Study of Pacritinib Versus Physician’s Choice in Patients with Myelofibrosis |
|
|
| Ongoing | 3 | 348 | Europe, RoW | Pacritinib, Ruxolitinib, Hydroxyurea, methylprednisolone, Dexamethasone, Prednisone, Capsule, hard, Tablet, Soluble tablet | CTI BioPharma Corp., CTI BioPharma Corp. | Primary Myelofibrosis, Post-essential thrombocythemia myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/μL), Post polycythaemia vera myelofibrosis, Primary or Secondary Myelofibrosis (MF), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
PACIFICA, NCT03165734 / 2017-001772-28: A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
|
|
| Recruiting | 3 | 399 | Europe, Canada, US, RoW | Pacritinib, Physician's Choice medications, corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib | CTI BioPharma, PSI CRO | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 06/25 | 12/25 | | |
|
| Active, not recruiting | 2 | 61 | Europe | Pacritinib | Stichting Hemato-Oncologie voor Volwassenen Nederland, Dutch Cancer Society, CTI BioPharma | Myelofibrosis | 07/23 | 02/27 | | |
NCT04282187: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms |
|
|
| Recruiting | 2 | 25 | US | Decitabine, 127716, 2''-Deoxy-5-azacytidine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ruxolitinib, 941678-49-5, INCB-18424, Jakafi, Oral JAK Inhibitor INCB18424, Fedratinib, 936091-26-8, SAR302503, TG101348, Questionnaire Administration, Pacritinib, 937272-79-2, Oral JAK2 Inhibitor SB1518, SB 1518, SB-1518, SB1518 | University of Washington | Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis | 11/26 | 11/26 | | |
BLAST, NCT04635059: Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer |
|
|
| Active, not recruiting | 2 | 6 | US | Pacritinib, SB1518 | Medical College of Wisconsin | Prostate Cancer | 11/23 | 05/27 | | |
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
|
|
| Recruiting | 2 | 118 | US | Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA | Karyopharm Therapeutics Inc | Myelofibrosis, Moderate Thrombocytopenia | 04/26 | 10/28 | | |
NCT04858256: Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms |
|
|
| Recruiting | 2 | 100 | US | Pacritinib | University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI) | T-Cell Neoplasm, Lymphoproliferative Disorders | 11/27 | 11/28 | | |
NCT06052618: Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) |
|
|
| Not yet recruiting | 2 | 65 | US | Pacritinib | National Cancer Institute (NCI) | KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease | 01/33 | 01/34 | | |
NCT02891603: A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression |
|
|
| Completed | 1/2 | 40 | US | Pacritinib, PAC, tyrosine kinase inhibitor (TKI), Sirolimus, Rapamune, Tacrolimus, Prograf, Allogenic hematopoietic cell transplant (alloHCT) | H. Lee Moffitt Cancer Center and Research Institute, CTI BioPharma, National Heart, Lung, and Blood Institute (NHLBI) | Graft Vs Host Disease, GVHD | 01/22 | 04/22 | | |
NCT04520269: A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR) |
|
|
| Recruiting | 1/2 | 74 | RoW | Pacritinib | National University Hospital, Singapore | Breast Cancer | 07/23 | 07/23 | | |
NCT05531786: Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) |
|
|
| Recruiting | 1/2 | 50 | US | Pacritinib | National Cancer Institute (NCI) | Graft vs Host Disease | 11/24 | 11/24 | | |
NCT06303193: Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms |
|
|
| Not yet recruiting | 1/2 | 160 | US | pacritinib | National Cancer Institute (NCI) | Myelodysplastic Syndromes | 01/30 | 01/35 | | |
| Recruiting | 1/2 | 26 | US | Pacritinib, Azacitidine | Douglas Tremblay, Sobi, Inc. | Chronic Myelomonocytic Leukemia | 07/25 | 05/27 | | |
NCT05657613: Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects |
|
|
| Completed | 1 | 60 | US | CYP450 Cocktail and Transporter Substrates with Pacritinib, Vonjo, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib | CTI BioPharma, PPD | Drug Interactions | 09/23 | 12/23 | | |
NCT06218628: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition |
|
|
| Recruiting | 1 | 24 | US | Talazoparib, talzenna, pacritinib, vonjo | Fox Chase Cancer Center | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis | 08/29 | 08/30 | | |
NCT05552183: Study to Evaluate the Safety, Tolerability, and PK of Pacritinib |
|
|
| Recruiting | 1 | 32 | US | oral dose of 200 mg pacritinib twice daily (BID) | CTI BioPharma, PPD | Hepatic Impairment | 05/24 | 05/24 | | |
NCT06414681: Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined |
|
|
| Not yet recruiting | 1 | 20 | NA | Tagraxofusp, Pacritinib | University of Kansas Medical Center | Myelofibrosis，MF | 12/25 | 12/26 | | |